Home Healthcare Car T Cell Therapy Market
car t cell therapy market

CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2021 – 2028

  • Published Date: Jun 2021
  • Pages: 108
  • Format: PDF
  • Report ID: PM1389
  • Base Year: 2020
  • Historical Data: 2017-2019

Market Segmentation

CAR-T Cell Target Antigens Outlook (Revenue, USD Million, 2017 – 2028)

  • CD19/CD22
  • BCMA (B-Cell Maturation Antigen)
  • Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13R?2, LewisY)

CAR-T Cell Indication Outlook (Revenue, USD Million, 2017 – 2028)

  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Acute Lymphoblastic Leukemia (ALL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Multiple Myeloma (MM)
  • Follicular Lymphoma (FL)
  • Others

CAR-T Cell Regional Outlook (Revenue, USD Million, 2017 – 2028)

  • U.S.
    • CAR-T Cell Target Antigens Outlook
      • CD19/CD22
      • BCMA (B-Cell Maturation Antigen)
      • Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13R?2, LewisY)
    • CAR-T Cell Indication Outlook
      • Diffuse Large B-Cell Lymphoma (DLBCL)
      • Acute Lymphoblastic Leukemia (ALL)
      • Chronic Lymphocytic Leukemia (CLL)
      • Multiple Myeloma (MM)
      • Follicular Lymphoma (FL)
      • Others
  • Europe
    • CAR-T Cell Target Antigens Outlook
      • CD19/CD22
      • BCMA (B-Cell Maturation Antigen)
      • Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13R?2, LewisY)
    • CAR-T Cell Indication Outlook
      • Diffuse Large B-Cell Lymphoma (DLBCL)
      • Acute Lymphoblastic Leukemia (ALL)
      • Chronic Lymphocytic Leukemia (CLL)
      • Multiple Myeloma (MM)
      • Follicular Lymphoma (FL)
      • Others
  • Japan
    • CAR-T Cell Target Antigens Outlook
      • CD19/CD22
      • BCMA (B-Cell Maturation Antigen)
      • Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13R?2, LewisY)
    • CAR-T Cell Indication Outlook
      • Diffuse Large B-Cell Lymphoma (DLBCL)
      • Acute Lymphoblastic Leukemia (ALL)
      • Chronic Lymphocytic Leukemia (CLL)
      • Multiple Myeloma (MM)
      • Follicular Lymphoma (FL)
      • Others
  • Rest of the World
    • CAR-T Cell Target Antigens Outlook
      • CD19/CD22
      • BCMA (B-Cell Maturation Antigen)
      • Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13R?2, LewisY)
    • CAR-T Cell Indication Outlook
      • Diffuse Large B-Cell Lymphoma (DLBCL)
      • Acute Lymphoblastic Leukemia (ALL)
      • Chronic Lymphocytic Leukemia (CLL)
      • Multiple Myeloma (MM)
      • Follicular Lymphoma (FL)
      • Others

Qualitative Analysis

  • Industry overview
    • Industry trends
    • Market drivers and restraints
    • Market size
    • Growth prospects
    • Porter’s analysis
    • PESTEL analysis
    • Key market opportunities prioritized
  • Competitive landscape
    • Overview
    • Financials
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecasts from 2020 to 2028
  • Market revenue estimates for target antigen up to 2028
  • Market revenue estimates for indication up to 2028
  • Regional market size and forecast for target antigen from 2020 to 2028
  • Regional market size and forecast for indication segments up to 2028
  • Company financials
Polaris Market Research
CAR-T Cell Therapy Market Size & Share | Global Industry Report, 2021 - 2028